Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Context Therapeutics Inc. (CNTX)

0.62   0.01 (1.66%) 03-24 16:00
Open: 0.5992 Pre. Close: 0.6099
High: 0.6273 Low: 0.5801
Volume: 49,522 Market Cap: 10(M)

Technical analysis

as of: 2023-03-24 4:24:58 PM
Overall:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 0.87     One year: 1.01
Support: Support1: 0.56    Support2: 0.46
Resistance: Resistance1: 0.74    Resistance2: 0.86
Pivot: 0.68
Moving Average: MA(5): 0.64     MA(20): 0.7
MA(100): 0.89     MA(250): 1.4
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 17.4     %D(3): 16.9
RSI: RSI(14): 33.3
52-week: High: 2.78  Low: 0.56
Average Vol(K): 3-Month: 2,066 (K)  10-Days: 93 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ CNTX ] has closed above bottom band by 17.7%. Bollinger Bands are 45.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 21 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.63 - 0.63 0.63 - 0.63
Low: 0.57 - 0.58 0.58 - 0.58
Close: 0.61 - 0.62 0.62 - 0.62

Company Description

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Headline News

Wed, 22 Mar 2023
Context Therapeutics Reports Full Year 2022 Financial Results and ... - GlobeNewswire

Fri, 17 Mar 2023
Context Therapeutics' Candidate CTIM-76 to Present at AACR ... - MyChesCo

Wed, 15 Mar 2023
Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 - Yahoo Finance

Mon, 13 Feb 2023
UPDATE -- Diamond Equity Research Initiates Coverage on Context Therapeutics Inc. (NASDAQ: CNTX) - Yahoo Finance

Mon, 06 Feb 2023
Context Therapeutics Highlights Clinical Responses from the Phase ... - GlobeNewswire

Tue, 31 Jan 2023
Context Therapeutics' Clinical Partner Stemline - GlobeNewswire

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 16 (M)
Shares Float 10 (M)
% Held by Insiders 6.1 (%)
% Held by Institutions 28.7 (%)
Shares Short 153 (K)
Shares Short P.Month 454 (K)

Stock Financials

EPS -3.12
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.38
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -39.8
Return on Equity (ttm) -80.2
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0
Operating Cash Flow -15 (M)
Levered Free Cash Flow -11 (M)

Stock Valuations

PE Ratio -0.2
PEG Ratio 0
Price to Book value 0.26
Price to Sales 0
Price to Cash Flow -0.68

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.